Novartis previously signed an agreement with CellforCure in July to produce CAR-T cell therapies including Kymriah (tisagenlecleucel) – which was the first CAR-T cell therapy approved by the FDA ...

Novartis’ CAR-T therapy Kymriah will be available in the US to adults with relapsed large B-cell lymphoma – bringing the cell therapy into direct competition with Gilead’s rival at exactly ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

While Gilead’s Tecartus and Novartis’ Kymriah also boast approvals in ALL, Autolus’ new med boasts a unique edge as the only CAR-T that doesn’t come with an FDA requirement for a Risk Evaluation ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

LEGN)), and Novartis’ Kymriah. These therapies are individually approved for multiple myeloma, large B-cell lymphoma, and other blood cancers. The FDA specifically instructs the companies to ...

He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah ®, the first FDA-approved CAR-T cell therapy. Eissa's expertise in ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

The United States Food and Drug Administration (USFDA) on Monday said that companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T ...